Kenneth Desart1, Georgios Rossidis1, Michael Michel1, Tamara Lux1, Kfir Ben-David2. 1. Department of Surgery, University of Florida, Gainesville, FL, USA. 2. Mount Sinai Medical Center, Comprehensive Cancer Center, 4306 Alton Road, 2nd Floor, Miami Beach, FL, 33140, USA. Kfir.bendavid@msmc.com.
Abstract
BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) has gained significant popularity in the USA, and consequently resulted in patients experiencing new-onset gastroesophageal reflux disease (GERD) following this bariatric procedure. Patients with GERD refractory to medical therapy present a more challenging situation limiting the surgical options to further treat the de novo GERD symptoms since the gastric fundus to perform a fundoplication is no longer an option. OBJECTIVES: The aim of this study is to determine if the LINX® magnetic sphincter augmentation system is a safe and effective option for patients with new gastroesophageal reflux disease following laparoscopic sleeve gastrectomy. SETTINGS: This study was conducted at the University Medical Center. METHODS: This is a retrospective review of seven consecutive patients who had a laparoscopic LINX® magnetic sphincter device placement for patients with refractory gastroesophageal reflux disease after laparoscopic sleeve gastrectomy between July 2014 and April 2015. RESULTS: All patients were noted to have self-reported greatly improved gastroesophageal reflux symptoms 2-4 weeks after their procedure. They were all noted to have statistically significant improved severity and frequency of their reflux, regurgitation, epigastric pain, sensation of fullness, dysphagia, and cough symptoms in their postoperative GERD symptoms compared with their preoperative evaluation. CONCLUSION: This is the first reported pilot case series, illustrating that the LINX® device is a safe and effective option in patients with de novo refractory gastroesophageal reflux disease after a laparoscopic sleeve gastrectomy despite appropriate weight loss.
BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) has gained significant popularity in the USA, and consequently resulted in patients experiencing new-onset gastroesophageal reflux disease (GERD) following this bariatric procedure. Patients with GERD refractory to medical therapy present a more challenging situation limiting the surgical options to further treat the de novo GERD symptoms since the gastric fundus to perform a fundoplication is no longer an option. OBJECTIVES: The aim of this study is to determine if the LINX® magnetic sphincter augmentation system is a safe and effective option for patients with new gastroesophageal reflux disease following laparoscopic sleeve gastrectomy. SETTINGS: This study was conducted at the University Medical Center. METHODS: This is a retrospective review of seven consecutive patients who had a laparoscopic LINX® magnetic sphincter device placement for patients with refractory gastroesophageal reflux disease after laparoscopic sleeve gastrectomy between July 2014 and April 2015. RESULTS: All patients were noted to have self-reported greatly improved gastroesophageal reflux symptoms 2-4 weeks after their procedure. They were all noted to have statistically significant improved severity and frequency of their reflux, regurgitation, epigastric pain, sensation of fullness, dysphagia, and cough symptoms in their postoperative GERD symptoms compared with their preoperative evaluation. CONCLUSION: This is the first reported pilot case series, illustrating that the LINX® device is a safe and effective option in patients with de novo refractory gastroesophageal reflux disease after a laparoscopic sleeve gastrectomy despite appropriate weight loss.
Authors: Luigi Bonavina; Tom DeMeester; Paul Fockens; Daniel Dunn; Greta Saino; Davide Bona; John Lipham; Willem Bemelman; Robert A Ganz Journal: Ann Surg Date: 2010-11 Impact factor: 12.969
Authors: Carlos Augusto S Madalosso; Richard Ricachenevsky Gurski; Sidia M Callegari-Jacques; Daniel Navarini; Guilherme Mazzini; Marina da Silva Pereira Journal: Ann Surg Date: 2016-01 Impact factor: 12.969
Authors: Daniel Moritz Felsenreich; Ronald Kefurt; Martin Schermann; Philipp Beckerhinn; Ivan Kristo; Michael Krebs; Gerhard Prager; Felix B Langer Journal: Obes Surg Date: 2017-12 Impact factor: 4.129